TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02731599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treadmill training with cues
Description: 20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
Study: NCT03750539

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard radiotherapy
Description: External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical hysterectomy
Description: Radical hysterectomy and pelvic and paraaortic lymph node resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy
Description: Radical hysterectomy and pelvic and paraaortic lymph node resection
Study: NCT02641938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
Study: NCT01102673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF-04991532 will be provided
Study: NCT03895515

Intervention type: DRUG
Intervention: Fiasp®
Description: Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
Study: NCT03037892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, Fentanyl
Description: Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, Remifentanil
Description: The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: The group 3 patient will receive only Remifentanil in the same doses as given in group
Study: NCT04524494

Intervention type: OTHER
Intervention: biopsy of intestinal tissue
Description: 4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)

Intervention type: OTHER
Intervention: biopsy of intestinal tissue
Description: 4 intestinal tissue biopsies taken from descending Duodenum, 2 intestinal tissue biopsies taken from Ileum, 2 intestinal tissue biopsies taken from ascending colon (additional to routine biopsies taken for gastrointestinal diagnostic)

Intervention type: OTHER
Intervention: blood draw
Description: 40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)

Intervention type: OTHER
Intervention: blood draw
Description: 40 ml blood draw (in Heparin blood tubes) (additional to routine blood draw taken for gastrointestinal diagnostic)

Intervention type: OTHER
Intervention: urine collection
Description: Midstream Urine collection

Intervention type: OTHER
Intervention: urine collection
Description: Midstream Urine collection
Study: NCT03199404

Intervention type: DEVICE
Intervention: TRAP
Description: Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
Study: NCT04562675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LHA intervention
Description: For the IG, a 4-hour lesson consisting of 4 chapters and leaflets was delivered over 4 weeks, with one chapter per hour per week. Each LHA visited the assigned mother in the IG four times in a 4-week period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: brochure-only
Description: brochure-only for control group (CG)
Study: NCT03844919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS + CBIT
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham rTMS + CBIT
Description: Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sham rTMS + CBIT
Description: Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
Study: NCT04008316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: colchicine 1mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: colchicine 1mg/day
Study: NCT02809989

Intervention type: DRUG
Intervention: Ovaleap®
Description: About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births).
Study: NCT03602950

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP
Description: autologous PRP will be injected subcutaneously before skin closure at time of elective CS
Study: NCT01859559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral intravenous access line placement
Description: The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral intravenous access line placement
Description: The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided peripheral intravenous access line placement
Description: The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Landmark Approach to peripheral intravenous access line placement
Description: ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Landmark Approach to peripheral intravenous access line placement
Description: ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Landmark Approach to peripheral intravenous access line placement
Description: ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
Study: NCT02348866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: method of laundering and donning scrubs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: method of laundering and donning scrubs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: method of laundering and donning scrubs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: method of laundering and donning scrubs
Study: NCT03074656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Description: Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
Study: NCT02190149

Intervention type: BIOLOGICAL
Intervention: ADVATE (Antihemophilic Factor [Recombinant])

Intervention type: BIOLOGICAL
Intervention: RIXUBIS (Coagulation Factor IX [Recombinant])
Study: NCT02155504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3700
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP3700
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3700
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT00706758

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS school
Description: Structured patient group education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IBS-guidebook
Description: Written information - IBS-guidebook
Study: NCT05682768

Intervention type: PROCEDURE
Intervention: Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures
Description: Adding suporting sutures between th posterior gastric wall and ancreatic stump in whipple procedure, the sutures are Duct to Mucosa Pancreatico-Gastrostomy with trans-pancreatic transverse mattress U- Shaped sutures.
Study: NCT02795065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
Study: NCT04010136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care training
Description: Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
Study: NCT00780104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin, Mitoxantrone, Etoposide, Cytarabine
Description: Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin + MEC
Description: Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
Study: NCT04655768

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palmar Plate Fixation
Description: Patients are treated by surgery (palmar plate)
Study: NCT05302102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral plyometric training
Description: The paretic-limb-only plyometric training group received a plyometric exercise program performed unilaterally through the paretic leg only for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral plyometric training
Description: The double-limb plyometric training group received a plyometric exercise program performed bilaterally through the paretic and non-paretic legs for 45 minutes, three times per week for 12 successive weeks. The training was conducted under close supervision of a licensed pediatric physical therapist according to safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The control group received the standard physical rehabilitation program conducted for 45 minutes, thrice a week for 12 consecutive weeks, and consisted of advanced balance training, gait training, postural and flexibility exercises, and strength training exercises.
Study: NCT04010136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care training
Description: Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative care training
Description: Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
Study: NCT03868579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Review medical chart

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoscopy
Description: Undergo pleuroscopy
Study: NCT01673425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine
Description: All participants will be given FluMist.
Study: NCT01184339

Intervention type: DEVICE
Intervention: MicroPhage S. aureus/MSSA/MRSA Blood Culture Test
Description: In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test.
Study: NCT03403478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LICE
Description: No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICE
Description: The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIE
Description: The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aquatic exercise training
Description: The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics.
Study: NCT03335397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M-learning application
Description: Mobile application with interactive contents available for android platform and Apple's operating system.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional learning process
Description: Traditional content available in university library.
Study: NCT04420208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Pap test
Description: Adding a non-painful step after the most uncomfortable phase of Pap smear
Study: NCT04027036

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliovirus vaccine in reduced doses
Description: contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated poliovirus vaccine in reduced doses
Description: contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age
Study: NCT01716949

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: 10 sessions, therapeutic time 60 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 250 mg/m\^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1650 mg/m\^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 50 mg/m\^2/d as 2-hour bolus infusion on d2, 9, 23, 30
Study: NCT02531503

Intervention type: OTHER
Intervention: Clinical asthma remission
Description: Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
Study: NCT04246541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients will receive IV ketorolac during surgery followed by 3 days of oral ketorolac (10 mg every 6 hours) for pain control. Patients will also be given oxycodone-acetaminophen (5mg-325mg) PRN for pain not controlled with ketorolac.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone-Acetaminophen
Description: Patients will be discharged with oxycodone-acetaminophen (5mg-325mg) PRN for pain control after surgery.
Study: NCT04346004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Participants in Control group are administered IV 100cc normal saline \& IM normal saline (1cc) 1 day before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Description: Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) \& IM Vitamin B12 (1mg) 1 day before surgery.
Study: NCT01066169

Intervention type: BIOLOGICAL
Intervention: Foceteria® (Novartis)
Description: This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.

Intervention type: BIOLOGICAL
Intervention: Foceteria® (Novartis)
Description: This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.